U.S. patent application number 10/330526 was filed with the patent office on 2003-05-22 for system for imaging malignant tumors using carbon 13 with mri.
Invention is credited to Ohkawa, Tihiro.
Application Number | 20030095923 10/330526 |
Document ID | / |
Family ID | 24960220 |
Filed Date | 2003-05-22 |
United States Patent
Application |
20030095923 |
Kind Code |
A1 |
Ohkawa, Tihiro |
May 22, 2003 |
System for imaging malignant tumors using carbon 13 with MRI
Abstract
In accordance with the present invention, a method for imaging a
malignancy in a patient, in situ, requires feeding the patient a
nutrient that is enriched with carbon 13 (.sup.13C). This feeding
step can be accomplished either orally or intravenously, and can
last for approximately 24 hours. Magnetic Resonance Imaging (MRI)
techniques are then used on the patient with rf energy that is
tuned to the nuclear resonance of .sup.13C. An image of selected
tissue in the patient is thereby created, and this image is
thereafter evaluated for any concentrations of .sup.13C that will
delineate a malignancy. If present, the malignancy can then be
treated. A subsequent (feeding)/(MRI imaging) procedure may be
performed. The image that is created in this subsequent procedure
can then be compared with the image that was created in the first
procedure to determine the efficacy of the treatment, or to
determine a growth rate for the malignancy.
Inventors: |
Ohkawa, Tihiro; (La Jolla,
CA) |
Correspondence
Address: |
Neil K. Nydegger
Nydegger & Associates
348 Olive Street
San Diego
CA
92103
US
|
Family ID: |
24960220 |
Appl. No.: |
10/330526 |
Filed: |
December 27, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10330526 |
Dec 27, 2002 |
|
|
|
09736526 |
Dec 13, 2000 |
|
|
|
6521210 |
|
|
|
|
Current U.S.
Class: |
424/9.3 ;
424/9.35 |
Current CPC
Class: |
G16H 20/60 20180101;
G16H 50/20 20180101; A61K 49/06 20130101; Y10T 436/24 20150115;
G16H 20/40 20180101; G16H 30/40 20180101; G16H 15/00 20180101; A61P
35/00 20180101 |
Class at
Publication: |
424/9.3 ;
424/9.35 |
International
Class: |
A61K 049/00 |
Claims
What is claimed is:
1. A system for identifying rapidly dividing cells of a malignancy
in in situ tissue of a patient, said system comprising: a nutrient
enriched with .sup.13C; means for administering said nutrient to
the patient for use by in situ tissue during cell division to
incorporate said .sup.13C into cells of the in situ tissue; means
for positioning the in situ tissue in a magnetic field; means for
radiating the in situ tissue in the magnetic field with rf energy,
the rf energy being tuned for nuclear resonance with .sup.13C to
create an image of the in situ tissue; and means for evaluating the
image for concentrations of .sup.13C therein to identify the
rapidly dividing cells.
2. A system as recited in claim 1 wherein said nutrient contains
glucose when the selected tissue is non fatty.
3. A system as recited in claim 1 wherein said nutrient contains an
amino acid when the selected tissue is fatty.
4. A system as recited in claim 1 wherein said nutrient is
administered orally.
5. A system as recited in claim 1 wherein said nutrient is
administered intravenously.
6. A system for identifying rapidly dividing cells in in situ
tissue of a patient which comprises: a nutrient enriched with
.sup.13C; a means for administering said nutrient to the patient to
provide .sup.13C for use by the in situ tissue during cell division
to incorporate said .sup.13C into cells of the in situ tissue; and
a means for detecting a concentration of said .sup.13C in the in
situ tissue to identify rapidly dividing cells in the in situ
tissue.
7. A system as recited in claim 6 wherein said nutrient contains
glucose when the selected tissue is non fatty.
8. A system as recited in claim 6 wherein said nutrient contains an
amino acid when the selected tissue is fatty.
9. A system as recited in claim 6 wherein said nutrient is
administered orally.
10. A system as recited in claim 6 wherein said nutrient is
administered intravenously.
Description
[0001] This application is a divisional of application Ser. No.
09/736,526, filed Dec. 13, 2000, which is currently pending. The
contents of application Ser. No. 09/736,526 are incorporated herein
by reference.
FIELD OF THE INVENTION
[0002] The present invention pertains generally to methods and
systems for diagnosing a malignancy in in situ tissue. More
particularly, the present invention pertains to methods and systems
for using carbon 13 (.sup.13C) as a target material for detecting
the presence of a malignancy in in situ tissue of a patient. The
present invention is particularly, but not exclusively, useful as a
method and a system for using MRI techniques to image
concentrations of .sup.13C in rapidly growing tissue.
BACKGROUND OF THE INVENTION
[0003] In normal healthy tissue, cells will grow, divide, and die
in an orderly manner. In this process, normal cell division is
necessary to sustain life and insure the orderly function of organs
and tissues. As is well known, when cell division occurs, the
result is the replication of a parent cell into daughter cells. The
daughter cells then continue to function in the same way as did the
parent cell. According to the type of tissue involved, however, the
rate of cell division for normal cells will differ. For example,
the rate of cell division in epithelial tissue and in bone marrow
tissue is more rapid than is the rate of cell division in other
tissues. In any event, for normal cell division, the cells of each
organ will replicate at a pre-programmed rate specific to that
organ. Unfortunately, however, it happens that for any number of
reasons the rate of cell division may change. In some cases, this
gives rise to rapidly growing cells whose rate of cell division is
out of control. As we know, cancer is one consequence of such rapid
cell growth, and cancer can take many forms. As we also know,
undetected and untreated cancer can be fatal.
[0004] Cell division requires nutrients, regardless whether the
tissue is healthy or cancerous. Importantly, carbon is an essential
element in these nutrients. Indeed, all cells contain carbon, and
about ninety percent of the carbon that is used by a cell can be
found in its structural components, such as the cell wall and the
nucleus. Further, it is known that when a cell grows and divides,
the structural components of the daughter cells are synthesized
from available nutrients. In fact, nearly fifty percent of the
carbon from a nutrient that has been used by a parent cell can be
found in each of the daughter cells.
[0005] Naturally occurring carbon is mostly in the form of the
carbon 12 isotope (.sup.12C). A small percentage of naturally
occurring carbon, however, is in the form of carbon 13 (.sup.13C).
Insofar as cell division is concerned, cells metabolize carbon 13
(.sup.13C) the same as they do the more common form of carbon,
.sup.12C. In at least one important respect, .sup.12C and .sup.13C
are different. Specifically, it happens that .sup.13C responds
particularly well to nuclear magnetic resonance, making it
particularly useful for MRI techniques. Thus, by tuning the rf
energy of an MRI for nuclear resonance with .sup.13C, images can be
created which react to the presence of .sup.13C in a tissue.
Fortunately, carbon with an increased concentration of the .sup.13C
isotope can be produced by physical and chemical means. In fact,
nutrients which are highly enriched with .sup.13C are commercially
available.
[0006] Normal cells divide at predetermined rates based on the type
of tissues to which they belong. In comparison with cells of the
same tissue, cancer cells divide at a much faster rate. In most
cases, these rapidly dividing cancer cells may take only about 8
hours to divide. Thus, in a 24 hour period they will divide about
three times. Consequently, when a patient is fed a nutrient
enriched with .sup.13C over a twenty-four hour period, there will
be a discernibly high concentration of .sup.13C. As a practical
matter, the new cells in a malignancy will be largely made of the
.sup.13C. A few hours after the feeding is interrupted, the unused
portion of the enriched nutrient will have been metabolized and
will disappear from the body.
[0007] A cell's use of nutrients is generally dependent on two
factors. One factor is the type of tissue, i.e. is the tissue fatty
or non-fatty tissue. The other factor, which is interrelated to the
first factor, concerns the type of nutrient that is used by the
tissue for cell division, e.g. glucose or amino acid. Thus, the
composition of nutrients to be used to target specific cells will
generally depend on whether the cells are fatty or non-fatty
tissue.
[0008] Heretofore, the detection of malignancies has been
accomplished in several ways, using either invasive or non-invasive
methods. Invasive techniques, such as the taking of a biopsy, have
been used extensively. Invasive techniques, however, can cause
varying degrees of extended patient discomfort. On the other hand,
non-invasive radiation techniques, such as X-ray and MRI, do not
involve extended discomfort, but they have been used with mixed
results. The difficulty here has been mostly in properly
interpreting the form and structure of target tissue to diagnose a
malignancy.
[0009] As just indicated, radiation methods for detecting
malignancies have depended on an interpretation of the morphology
of the tissue. For instance, to image tissue, X-ray technology
depends on the density of the tissue being targeted. MRI, on the
other hand, relies on the reaction of protons in the target tissue
to a magnetic field, in order to image the tissue and thereby
determine its morphology. Using either technique, however, when a
malignancy has not grown to a size which can distinguish it from
the morphology of surrounding tissue, presently used radiation
techniques may be inadequate. Stated differently, presently used
radiation techniques for distinguishing the morphology of a tissue
have been generally unsatisfactory for detecting cancerous cells
during their earliest rapid growth stages.
[0010] In light of the above, it is an object of the present
invention to provide a method for the in situ imaging of a
malignancy in a patient that is independent of the morphology of
the tissue. Another object is to provide a method and a system for
targeting cells in an in situ tissue, according to the composition
of the tissue. A further object is to provide a method for the in
situ imaging of a malignancy wherein a nutrient is selected to
identify rapidly growing cells based upon their use of the selected
nutrient in cell division. Another object is to provide a method
for determining the growth rate of target cells in in situ tissue.
Yet another object is to provide a method and a standard for
determining the efficacy of a treatment of a malignancy in a
patient.
SUMMARY OF THE PREFERRED EMBODIMENTS
[0011] A system and method for identifying rapidly dividing cells
in in situ tissue in a patient in accordance with the present
invention requires feeding the patient a nutrient enriched with
.sup.13C. According to well known functions of cellular physiology,
the .sup.13C enriched nutrient will then be used by the cells of
the in situ tissue to incorporate the .sup.13C into the cells that
result from cell division.
[0012] Typically, the feeding of the patient extends over a period
of 24 hours, and can be accomplished either orally or
intravenously. Further, it is desirable to use nutrients containing
glucose enriched with .sup.13C when the target tissue is non fatty,
and to use nutrients containing amino acid enriched with .sup.13C
when the target tissue is fatty.
[0013] After the nutrient enriched with .sup.13C has been
assimilated by the patient, the method of the present invention
envisions using well known MRI techniques for the purpose of
imaging the tissue containing .sup.13C. These MRI techniques
include placing the target tissue of the patient to be imaged in a
magnetic field. This portion of the patient is then radiated with
rf energy that is tuned for nuclear resonance with .sup.13C. An
evaluation of the resultant image for concentrations of .sup.13C
within the target tissue will determine whether there is rapid cell
growth in the target tissue.
[0014] The system of the present invention also envisions a
possible subsequent procedure, to determine the growth rate of a
tumor or to evaluate treatment efficacy. Specifically, after a
first procedure has been completed, and after a predetermined
period of time, the patient is again fed a nutrient enriched with
.sup.13C over a twenty-four hour period. Again, the target tissue
is imaged using MRI techniques. The image thus created in the
second procedure is then compared with the image that was created
in the first procedure. Based on this comparison, the change in the
concentration of .sup.13C can then be measured to determine the
growth rate of the tumor. Alternatively, the comparison can be made
to show an absence or presence of rapidly growing tissue to
determine the efficacy of a treatment.
BRIEF DESCRIPTION OF THE DRAWINGS
[0015] The novel features of this invention, as well as the
invention itself, both as to its structure and its operation, will
be best understood from the accompanying drawing, taken in
conjunction with the accompanying description, in which similar
reference characters refer to similar parts, and in which:
[0016] The Figure is a logic diagram of the steps involved in the
method of the present invention.
DESCRIPTION OF THE PREFERRED EMBODIMENT
[0017] A method for performing the steps of the present invention
is shown in diagram form in the Figure and is generally designated
10. As indicated in block 12, the method 10 begins with a
determination by a physician that a patient has a target tissue
that may contain a possible malignancy. Once the target tissue has
been identified, the inquiry diamond 14 indicates that the question
is presented as to whether the target tissue is fatty. If the
target tissue is non-fatty, block 16 of method 10 indicates it is
necessary to use nutrients containing glucose enriched with
.sup.13C. When the tissue is fatty, however, inquiry diamond 14 is
directed toward block 18 which indicates that a nutrient containing
amino acids enriched with .sup.13C is to be selected. Upon
selection of the desired nutrient, feeding the patient is initiated
as indicated by block 20. The feeding step 20 is typically
accomplished over a period of twenty-four hours, and can be
accomplished either orally or intravenously. As indicated by block
22, at a predetermined time following the feeding (block 20),
allowing for the unused portion of the of the enriched nutrient to
disappear from the body, the step of radiating the target tissue is
performed.
[0018] Also shown in the Figure at inquiry diamond 24, the inquiry
is made as to whether this is a second procedure. Accordingly, if
the answer to this inquiry 24 is no, a first image is created as
indicated by block 26. Specifically the present invention requires
imaging with an MRI that is tuned for nuclear resonance with
.sup.13C. Creation of the first image (block 26) is followed by
another inquiry, diamond 28, regarding the presence of rapid cell
growth as delineated in the first image. If the answer to the
inquiry (diamond 28) regarding the presence of rapid cell growth is
"no," the method 10 is concluded, as indicated by the oval 30
marked "End." If, on the other hand, the answer to the inquiry
(diamond 28) regarding rapid cell growth is "yes," a subsequent
procedure is performed.
[0019] Depending on the information desired, if it is determined
that rapid cell growth is present (inquiry diamond 28), the patient
may be treated for the malignancy, as indicated by block 32.
According to the parameters of a given treatment, after treating
the patient (block 32), the steps of the first procedure are
repeated. These steps are namely feeding the patient a nutrient
enriched with .sup.13C (block 20) and radiating the target tissue
(block 22). Upon completion of the radiation of the target tissue
(block 22), the determination is again made concerning whether this
is a second procedure (inquiry diamond 24). The answer to this
inquiry for a subsequent procedure will be "yes," and as indicated
by block 34, a second image will be created. The first image and
the second image are then compared (block 36), to determine the
treatment efficacy (block 38). As shown in the Figure, this could
end the process (oval 30).
[0020] It is also envisioned by the method 10 of the present
invention, that it may be desirable to ascertain the growth rate of
the malignancy. In this case, upon receiving a positive response
for inquiry diamond 28, the method 10 will conduct a subsequent
procedure. This subsequent procedure requires the steps of feeding
the patient a nutrient enriched with .sup.13C (block 20) and
radiating the target tissue (block 22). Once again, the answer of
inquiry diamond 24 will be "yes," and as indicated by block 34, a
second image is created. Following the creation of the second image
(block 34) the first and second images are compared (block 36). As
shown in the Figure at block 40, the growth rate can then be
determined and the process will have reached the end, indicated by
oval 30.
[0021] While the particular method for imaging in situ imaging
malignant tumors using carbon 13 with MRI as herein shown and
disclosed in detail is fully capable of obtaining the objects and
providing the advantages herein before stated, it is to be
understood that it is merely illustrative of the presently
preferred embodiments of the invention and that no limitations are
intended to the details of construction or design herein shown
other than as described in the appended claims.
* * * * *